Mölnlycke – world-leading medical solutions company

Around the world, healthcare systems and professionals are under pressure to deliver better care, to more people, for better value. They need innovative solutions they can trust. That’s where we come in. We are here to advance performance in healthcare. So we are always on the lookout for new ways to improve. Our focus: providing effective solutions and offering better value for money.

Solutions to improve outcomes

We have one purpose – to advance performance in healthcare across the world. We want to ensure that healthcare professionals have what they need to achieve the best clinical, patient and financial outcomes. But different healthcare professionals have different needs. We start by listening and making sure we understand them. Then we create solutions that are right for them and for their patients, and that are supported and backed up by clinical evidence.

Our surgical products are marketed to hospitals and healthcare providers in the acute sector, while our wound care and pressure injury prevention products are aimed at both eh acute and the community healthcare sectors. In many markets, like Australia & New Zealand, tenders are used to procure our solutions.

We contribute to advancing performance in other ways too. By sharing knowledge about our specialist clinical areas. And by helping to shape healthcare policies and protocols to raise standards of care worldwide. We have a strong commitment to healthcare professionals.

Shaping the market

Since we launched the world’s first gently adhering silicone dressing in 1989, Mölnlycke has helped to relieve pain and suffering for millions of patients around the world. Today, we continue to innovate, with dressings to stay on longer and enable patients to move more easily, for added comfort and enhanced healing.

Better care for more people

Our goal is also to increase the overall health economics value of our solutions for society while reducing patient suffering. Mölnlycke’s focus on chronic wounds, such as diabetic foot ulcers, is an example of this. Today, diabetic foot ulcers have a higher mortality rate than both breast and prostate cancer. Mepliex® Border Flex, promotes undisturbed healing of foot ulcers and other chronic wounds. This creates great conditions for healing and wound closure and has a positive impact on health economics by freeing up staff time.

There are examples within our surgical portfolio too. Mölnlycke® procedure packs are recognised for improving efficiency in the operating theatres by reducing surgery preparation time by 40% – and thereby increasing the number of surgical procedures that can take place.

By improving health and health economics outcomes. We also do everything we can to contribute to the UN’s global sustainability goal #3: “Good health and well-being for all”. We are aware that the population of some countries do not have access to our world leading solutions for political and economic reasons. We are working to increase availability through NGOs and other partners around the world.

A global company with a Swedish heritage

Customers use our solutions in almost 100 countries – and we own operations in more than 40 of them. Although we are a global company, our headquarters are still based in Gothenburg (Sweden) – just a short distance from the town of Mölnlycke- the place where the company was founded in 1849 and the origin of the Mölnlycke name.

As a Swedish company, responsibility for our employees is second nature. We employ almost 8,000 people around the world, with significant employee numbers in Malaysia, Thailand, the Czech Republic, Sweden and Finland. Our goal is to create an environment where our employees feel empowered to grow and develop to their full potential.

Mölnlycke Downunder

In 2001, Mölnlycke acquired a clinical brand that led to expansion outside of Europe. This resulted in the subsequent creation of Mölnlycke Pty. Ltd in 2003, to manage regional business operations. Since then, we have gone from strength to strength and have established ourselves as market leaders in several categories.

Mark Cortiula, Managing Director ANZ, says:

“Our success is due to the passionate local team who embody the company’s mission to support health care professional in achieving superior clinical and cost-effective outcomes.”

Our corporate social responsibility: Changing lives

Mölnlycke feels a strong sense of commitment to both the medical profession and patients receiving treatment. Through our global and local charity partners, we seek to have a long-term positive impact. We also invest in the communities where we operate so we remain a trusted partner over the long term. For several years, we have supported two organisations representing key patient groups as our official global charity partners:

  • Debra, a worldwide network of national groups that strives to improve quality of life for people with the rare generic skin disease, Epidermolysis Bullosa (EB)
  • Operation Smile, a medical volunteer organisation that provides free reconstructive surgery for children born with facial deformities such as cleft lip and cleft palate.

By walking, baking, running and more, in 2019, Mölnlycke employees managed to raise €70,000. The company added another €120,000 to the fundraising campaign, meaning a total of €190,00 (or approximately $308,000 AUD) was donated to Debra and Operation Smile.